Antibody-based inhibition of ADAM10 as cancer immunotherapy [ 2014 - 2017 ]

Research Grant

Researchers: A/Pr Martin Lackmann (Principal investigator) ,  Dr Peter Janes (Principal investigator) ,  A/Pr Robert Moritz ,  Dr Mary Vail ,  Prof Andrew Scott
View all 6 related researchers

Brief description Despite our advances in understanding the molecular basis of cancer, treatments for metastatic cancers are limited, emphasising an urgent need for strategies targeting several oncogenic pathways. We generated monoclonal antibodies effectively blocking the activity of ADAM10, an oncogenic cell surface protease that activates tumour growth, invasion and metastasis through multiple pathways. Here we describe the strategies that progress these antibodies as lead therapeutics for clinical testing.

Funding Amount $AUD 652,788.86

Funding Scheme Project Grants

Notes Standard Project Grant